Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. - Wikidata - wikimedia - TriplyDB

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

http://www.wikidata.org/entity/Q37660900

about

Immunogenetics of type 1 diabetes mellitus Type 1 diabetes mellitus.Can non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?Gene and protein expression of a soluble form of CTLA-4 in a healthy dog Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.Immune therapy for treating type 1 diabetes: challenging existing paradigms.Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases.β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.Thinking bedside at the bench: the NOD mouse model of T1DM.Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis.Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.Type 1 Diabetes--Reaping the Rewards of a Targeted Research Investment.What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters.B-lymphocyte depletion with rituximab and β-cell function: two-year results Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray.Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus.Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development.Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.CD28 Costimulation: From Mechanism to Therapy.Current and future efforts toward the prevention of type 1 diabetes.Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.Restoring Regulatory T Cells in Type 1 Diabetes.Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.T Cell Receptor Profiling in Type 1 Diabetes.Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes.Understanding and preventing type 1 diabetes through the unique working model of TrialNet.Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.World Diabetes Day: Perspectives on immunotherapy of Type 1 Diabetes.Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells.Complete loss of insulin secretion capacity in type 1A diabetes patients during long-term follow up.Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.Haploinsufficiency of interferon regulatory factor 4 strongly protects against autoimmune diabetes in NOD mice.

P2860

Q28087365-F2B29ABD-AE79-493D-99E0-428051DD962E Q30235021-75D4858B-1A8A-4A19-9E72-923709CBC37C Q30252380-842E3673-0FCB-43FE-9E9C-9FBF6AE8DFE3 Q33737335-9BEC832C-22FD-42B7-8841-D9E957D602E9 Q34393377-76D534DE-D5CB-49C1-A9FA-2A424FD641C0 Q34818608-C0E23A3B-D2BF-4D99-A5DC-7A2BA971F519 Q35242386-5347F92E-0FF2-4EBD-897A-69F229394221 Q35242428-80226078-2F05-4331-A8DD-8AA9393AF977 Q35739662-8D6C461F-53D4-41E1-9047-EB04BF8B3025 Q35904021-DA2648F4-A72E-47A6-8246-A02218E5C375 Q35911875-F56986DD-09AD-4F78-8B31-37BBD221F942 Q36092234-8C5F6FCA-23E0-4A9C-81B2-E2D9243987E5 Q36117948-A14EC3E8-38EC-48DB-9FD4-62180E026EE7 Q36216535-65F15E96-E7AA-4359-AF14-334E96215113 Q36908165-7DDB0E0F-33D5-4CD8-8BAC-E28C8C85BADC Q36913132-8E37A45A-A92F-49E5-B6E2-4CDB38F0F09C Q36919720-9C576D17-B2DF-42B3-B924-D6EF8380D241 Q36926214-5FC31D7A-5AFD-4C4D-B82E-86DBDF5C3221 Q37412811-BA597A74-0FBA-4155-BF62-731A0704D3D0 Q37504134-BC954B95-8EF2-4FFD-8696-FE2404A25F2F Q38262670-CBE12B6D-D9D2-4B9E-960D-A36B0B14A6B2 Q38365047-F40BBD73-3E05-4B68-AC4C-CC19840DE674 Q38387552-D0C34007-CE7C-451D-9AE9-5E50F2624785 Q38806457-088ECCFD-1529-47F6-9231-3884F220C4C7 Q38828063-EE1A6CB1-945C-4CA2-A0E2-C62A6FC69AF2 Q38837466-6A50F485-6BE0-4DA3-A6C7-AFCF13EEC0B2 Q38842306-1DC8EEAF-B038-41D9-A74B-C1E023712DE3 Q38927961-DBE9DCD0-5258-4F41-A141-889EFD91E5C6 Q38963375-2C3B88E9-9E62-4692-AF2C-5FD05413E56C Q39596760-0BDD38F7-1078-4360-B8AF-BB575C1208A4 Q42374922-DACAFCF1-FA45-4CD2-9187-B84914AF1270 Q45818945-C4D5F96F-D438-4ED4-928A-CAED2BA13D6F Q46486153-56441130-21DA-4601-98B3-E5E4B99F90E0 Q47375383-4254B4C0-CD9F-419F-9E59-B62D21EB0DCF Q47385058-C94FADEC-1EB6-4474-8D6C-3B1597B38211 Q47889466-C7F5D372-B7C9-4792-9E4D-2380DAB55380 Q48175684-23443179-11C3-47BE-BF3E-793D85A39A57 Q48183875-0B1ED6CD-F54C-4234-A1A7-57C7E666A74E Q50077957-160F1EC1-BBF0-4099-9742-48777E58043D Q50946212-9343A881-E3CC-4A5B-B059-0C7DAFC522B9

P2860

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

http://www.wikidata.org/entity/Q37660900

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Costimulation modulation with ...... after cessation of treatment.

@en

Costimulation modulation with ...... after cessation of treatment.

@nl

type

label

Costimulation modulation with ...... after cessation of treatment.

@en

Costimulation modulation with ...... after cessation of treatment.

@nl

prefLabel

Costimulation modulation with ...... after cessation of treatment.

@en

Costimulation modulation with ...... after cessation of treatment.

@nl

P1433

Q37660900-D06B17B5-8DF3-433D-9520-B9DDB50A42EA

P1476

Q37660900-5293046A-087F-43A2-A9AA-4533D6718EE8

P2093

Q37660900-17DDF8AB-AF2C-4D59-8C2C-94B2C1239706

Q37660900-51CCC274-D03D-495F-B1D0-B70B05689629

Q37660900-523D56A1-B056-4E8D-942D-D4F82AA27DAD

Q37660900-6387873D-A62E-4AA2-9D2B-A1A3DABFBE68

Q37660900-7F415EDE-AA4A-464B-BC9B-EB6EA7D66365

Q37660900-866E2DD4-2245-4DB0-90CF-30D1922AC053

Q37660900-94EB764F-727A-4098-925C-E50EC10C1E0C

Q37660900-964D32BB-97AE-4ED8-8E13-42008129D608

Q37660900-A0DC2656-AA3E-425C-A9A2-E139A2884F7F

Q37660900-AECD9434-E7BD-4EFB-A935-E12C9F8B640F

P2860

Q37660900-1181402D-66A6-4248-AD1A-B2FCD7ACE63B

Q37660900-3D9BF4FE-3CB7-4CDB-AFB6-EEC29BCA26EE

Q37660900-4F7CACF0-0237-4322-8BF8-A959F4A26BC7

Q37660900-617E5814-4A6E-4BB4-B5BB-B94CA0BC0347

Q37660900-695C2B07-82EC-4B57-82E7-9F5D6EA51706

Q37660900-74A30BE0-6BC5-4DDB-B426-39E8547E7566

Q37660900-805CCB19-3BF6-41BB-A590-AB3AF91711EF

Q37660900-880703CB-EC06-4E35-9716-146047D053F9

Q37660900-8E500865-9224-406A-B6BE-70A5F3DE5C59

Q37660900-9DFC7090-CCA8-413D-95D3-E19CDBE630BB

P304

Q37660900-F545DCCC-09D8-4B49-8B40-E52A678AB0F1

P31

Q37660900-65002F25-8631-471F-99D5-E6808C0E880E

P356

Q37660900-C47AF8A2-3F59-4F56-94BE-7D0DE28C91BA

P407

Q37660900-4C6AF164-D07A-4A72-8376-79786F276BF0

P433

Q37660900-885B632D-4D0D-49D1-BEE2-3B140A038B11

P478

Q37660900-12CE303C-9365-4D42-A254-F57AAEC73C87

P50

Q37660900-3C2AEBD4-39F2-47C9-9C73-66E6B6A43AEE

Q37660900-48B0EB96-7048-4F08-AF39-52F05A41BCC8

Q37660900-DD6B5CB4-D55B-4EBC-BA12-814B6BFEF4F9

Q37660900-EB126D49-7960-4489-835A-EDD761C03CEF

P577

Q37660900-4181A8DE-E3F6-4D77-AAFF-0E125C9A830B

P5875

Q37660900-F11E6708-19E3-4E78-A156-CAAE5846BDD9

P698

Q37660900-1AC0336E-B435-4E6F-ABBB-F3E4ADC11257

P921

Q37660900-355F3E28-C7FD-42F7-A0C2-94571B4F31A3

P932

Q37660900-2DA8249C-97E8-4CCA-BA9C-AC74BD267116

P356

P1433

P1476

Costimulation modulation with ...... after cessation of treatment.

@en

P2093

Antoinette Moran

http://www.w3.org/2001/XMLSchema#string

Brian Bundy

http://www.w3.org/2001/XMLSchema#string

Carla J Greenbaum

http://www.w3.org/2001/XMLSchema#string

Darrell M Wilson

http://www.w3.org/2001/XMLSchema#string

Diane K Wherrett

http://www.w3.org/2001/XMLSchema#string

Dorothy J Becker

http://www.w3.org/2001/XMLSchema#string

Jay S Skyler

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Krischer

http://www.w3.org/2001/XMLSchema#string

Jennifer B Marks

http://www.w3.org/2001/XMLSchema#string

Peter A Gottlieb

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Genetics, pathogenesis and clinical interventions in type 1 diabetes

Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis.

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

P304

1069-1075

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-0604

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Linda A. DiMeglio

P577

2013-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262045451

http://www.w3.org/2001/XMLSchema#string

P698

24296850

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3964491

http://www.w3.org/2001/XMLSchema#string